Login to Your Account


Skin tight: Debt hits derm, quiz Valeant 'core' values in $2B-plus assets sell-off

By Randy Osborne
Staff Writer

Wednesday, January 11, 2017

During a third-quarter earnings conference call in November with investors, when asked about divestitures that could help the company chip away at major debt and focus on the main business, Valeant Pharmaceuticals International Inc. CEO Joe Papa said "core assets for us are the dermatology, the gastrointestinal [GI], the eye-care and the consumer side, but we did receive a number of inbound requests to acquire some of our product assets with very significant numbers that we have to evaluate."

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription